Ginkgo Bioworks, Inc.

Join us down in the Boston Seaport this Thursday, May 1 for Engineering Biology Club! This month: "Principles for introducing new genes and species for conservation" with Sebastian Kamau of the MIT Media Lab https://lnkd.in/eS7GVWd6

Ginkgo @ PEGS Boston 2025! Don’t miss our team as they showcase how Ginkgo’s high-throughput datasets are fueling AI/ML pipelines in antibody development. 🎤 Catch the talk: "A High-Throughput Antibody Developability Data Generation Platform for AI/ML Model Training and Drug Discovery" 📅 May 14, 2025 | 3:30 PM

Interested in what we have been up to at Ginkgo Datapoints? Wondering which partners are well positioned to support the scale of data generation required for modern drug discovery and development? We'd love to connect at the upcoming #PEGS conference and share what we've built.

We’re thrilled to share that Ginkgo Bioworks’ Automation team is partnering with Aura Genetics, a high-complexity diagnostic laboratory, to design and deploy a Reconfigurable Automation Cart (RAC) system. This flexible automation solution is a key enabler in Aura’s collaboration with UPS Healthcare to support the rapidly growing at-home testing and wellness market—and to accelerate the delivery and turnaround time of diagnostic results. With support from Ginkgo’s automation engineers and scientists, Aura Genetics will be equipped to scale up high-throughput workflows and process thousands of samples per day with speed and precision. Read more about it here: https://lnkd.in/e4baFfnm

Join us May 1st at Engineering Biology Club! This month: "Principles for introducing new genes and species for conservation" by Wakanene Kamau of the MIT Media Lab. Register here to attend 👇 https://lnkd.in/eS7GVWd6

"Data is our currency" - curious about how data and AI are reshaping pharma and accelerating scientific discovery? Listen in to a conversation between John Androsavich, General Manager of Ginkgo Datapoints, and Jonah Comstock from pharmaphorum.

A cellular masterpiece! 🎨 Can you guess the cell type? Take a closer look at this Cell Painting image. By using fluorescent dyes to illuminate key cellular structures, cell painting offers a window into complex cell morphology. Capturing thousands of features, Cell Painting helps decipher drug effects on cell morphologies.  Now, imagine this power scaled up. Our upcoming GDPx3 dataset does exactly that! It features dose-response profiles for small molecules across multiple cell types and 2 timepoints – including challenging primary cells.   Ginkgo Datapoints' high-throughput automation and cell engineering expertise make this possible, delivering AI-ready data to accelerate your drug discovery.  Get ready to unlock novel insights with GDPx3! Share your cell type guess below! 👇and be on the lookout for GDPx3 in the coming weeks! Learn more: https://lnkd.in/eBf5r2V9

RNA sequence space is vast. How are you navigating mRNA therapeutic design? Designing the most effective sequence for your therapy is challenging. AI can help, but only if it’s trained on the right data. Public datasets might get you started, but they won’t help you refine your models or explore novel synthetic sequence designs. That’s where Ginkgo’s mRNA Data Generation platform comes in. We can generate high-throughput data on in-cell mRNA stability and translation efficiency for tens of thousands of your UTR designs in a single experiment – without the overhead of setting up and running your own assays. 🚀 Better data > Better models > Better RNA therapeutics Download a sample dataset and learn more: https://lnkd.in/gd34wAEN Or reach out to Swaminath Srinivas to discuss your custom data needs.

Ginkgo Bioworks, Inc. founder Jason Kelly at the #NSCEB AI+Biotechnology Summit: "Genetic engineering is a technology like fire or electricity – you can use it for almost anything. If you want to unlock the potential, you need to regulate the end products, not just the technology itself." The transformative applications of biotechnology are limitless, yet our current regulatory framework hinders innovation by focusing on process rather than outcome. For a resilient bioeconomy and strong biosecurity infrastructure, we need regulation that centers the safety and utility of the end products, not the methods used to create them. Watch his conversation with John Cumbers (SynBioBeta) here: https://lnkd.in/g9Ah5C4P #Biosecurity #AI #Biotech #NationalSecurity

What if your next prescription came from an American wheat field rather than a foreign factory? That future is closer than you think. Ginkgo Bioworks and partners are proud to announce $29M partnership with Advanced Research Projects Agency for Health (ARPA-H) to create distributed, on-demand manufacturing of essential medicines using wheat germ cell-free systems. Read the full press release here: https://lnkd.in/e5AUVPxZ The WHEAT project represents a fundamental shift in how critical medications reach patients, by shifting production from overseas factories to American biotech facilities powered by American agriculture. The outcome? Critical medicines that are produced from a more resilient, domestic supply chain, cost less and are more widely available.